Insulet

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Insulet (PODD) reports record-breaking Q4 earnings, eyes international expansion

Insulet's Q4 2022 earnings call highlighted exceptional revenue growth, strong customer adoption of Omnipod 5, and a focus on customer-centric innovation. While facing challenges with device corrections and FDA approval timelines, the company remains optimistic about revenue growth, margin improvement, and strategic investments in innovation and expansion.

Insulet reports robust Q1 growth, eyes global expansion opportunities

Insulet's Q1 2023 showcased strong financials, driven by Omnipod 5 success and U.S. market growth.
Optimism for future growth, market leadership, and expansion into underpenetrated global markets.
Challenges include declining drug delivery business and the need for continued innovation and market penetration strategies.

Insulet reports robust Q2 earnings, eyes European expansion and innovation

Insulet's Q2 performance exceeded expectations, driven by strong revenue growth and the success of Omnipod 5, showcasing the company's market strength and innovation.
While facing challenges such as inventory management and uncertainties around new products like Omnipod GO, Insulet remains optimistic about its growth trajectory and international expansion.
The company's strategic focus on consumer needs, continuous innovation, and expansion into new markets position it well for sustained leadership and revenue growth in the diabetes management sector.

Insulet excels in Q3 with Omnipod 5 driving growth

Insulet's Q3 performance was robust, driven by Omnipod 5 success.
Confidence in growth outlook, financial strength, and market positioning.
Challenges include competition, timing guidance, and market penetration.
Opportunities lie in basal market expansion and international growth potential.

Insulet (PODD) reports stellar Q4 results and eyes global expansion

Insulet's Q4 2023 performance was robust, driven by strong revenue growth and milestone achievements.
The company's strengths lie in its focus on innovation, market positioning, and strategic partnerships.
Challenges include optimizing resource allocation, reimbursement negotiations, and meeting high demand.
Opportunities for Insulet include expanding digital capabilities, driving innovation, and capturing market growth.

Insulet (PODD) reports record Q3 revenue and outlines growth strategies

Insulet's Q3 performance exceeded expectations with strong revenue and margin growth.
The company's focus on expanding Omnipod 5 platform and international growth is key.
Challenges include maintaining growth rates and sustaining pricing benefits.
Opportunities lie in accelerating international expansion and enhancing customer experience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Insulet (PODD) Q1 2019 Results - Earnings Call Transcript

Insulet (PODD) delivered earnings and revenue surprises of 250.00% and 3.39%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Insulet (PODD) Q1 Earnings and Revenues Beat Estimates

Insulet (PODD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why the Earnings Surprise Streak Could Continue for Insulet (PODD)

Insulet (PODD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Insulet (PODD) Up 5.1% Since Last Earnings Report?

CVS Health

HealthEquity

Find out why our Motley Fool contributors called out these three businesses as top opportunities right now.

3 'Top Healthcare Stocks' to Buy in March

News for Insulet Stock (PODD)